DEVONIAN HEALTH GROUP INC.

 

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

Devonian Health Group’s Purgenesis™ anti-aging derma-cosmeceutical treatment is now recognized through the Canadian Dermatology Association Skin Health Program

 

Québec, Québec – September 6, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXV: GSD) a clinical stage botanical pharmaceutical corporation, is pleased to announce that its Purgenesis™ anti-aging three-cream treatment is now recognized by the Canadian Dermatology Association (CDA) through its Skin Health Program.

‘‘Devonian’s mission is to develop innovative products that contribute to people’s well being. Skin being the largest organ of the human body, it requires special care like any other organ. Devonian develops its dermo-cosmeceutical products with the highest pharmaceutical standards.  We cooperate with health-care professionals to bring added-value products to people. Purgenesis™ treatment can now bear the Skin Health Program seal of recognition, awarded after a thorough review of our treatment formulation by the CDA Skin Health Expert Advisory Board” states Dr Andre P. Boulet, PhD, President & CEO of Devonian.

“The CDA welcomes the addition of Purgenesis™ treatment to the Skin Health Program, a program that identifies products that are fragrance-free or unscented, have a low potential for irritation and do not contain the most common contact allergens” says Dr Ian Landells, certified Dermatologist and Chair of the Skin Health Program.

‘‘The Purgenesis™ brand should be marketed in Canada exclusively through certified dermatologists’’ added Dr Boulet.

 

About Purgenesis™ anti-aging treatment

Purgenesis™ anti-aging treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome® complex, an active structure extracted from organic baby spinach.  The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, long-lasting anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to evaluate the performance of Purgenesis™ Anti-aging product line compared with two other leading prestige brands over a 28-day period of use.  The results indicate that Purgenesis™ anti-aging line is significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration effects. Purgenesis™ anti-aging treatment is patent-pending worldwide with the exception of Japan where a patent was issued (#JP 5952261).

 

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
 

Contact:
André Boulet
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com